We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Parker Laboratories

Manufactures medical ultrasound and electromedical contact media, including gels, solid gels, lotions and pads read more Featured Products: More products

Download Mobile App




Parker Labs in Alliance for Ultrasound Probe Disinfectant

By MedImaging International staff writers
Posted on 19 Jul 2022
Print article
Image: Tristel Duo ULT offers high-level disinfection for all parts of an ultrasound transducer (Photo courtesy of Tristel)
Image: Tristel Duo ULT offers high-level disinfection for all parts of an ultrasound transducer (Photo courtesy of Tristel)

Parker Laboratories Inc. (Fairfield, NJ, USA) and Tristel plc (Newmarket, UK) have entered into a commercial partnership in which Tristel will manufacture and distribute its high-level ultrasound probe disinfectants.

Tristel is a UK-based manufacturer of infection prevention products. Ultrasound probe disinfection is one of Tristel's most important areas of focus within the hospital infection prevention market, accounting for approximately 40% of the company's global revenues. Parker is a leading manufacturer in the US market for the conductive gels and sheaths that are used in all ultrasound procedures, with a nationwide distribution network.

Tristel has submitted its De Novo request for approval to the US FDA for Tristel Duo ULT, a high-level disinfectant foam that can be used on ultrasound probes used for intra-cavitary and skin surface diagnostic procedures. To Tristel’s knowledge, Tristel Duo ULT is the first disinfectant to make a De Novo request to the FDA, reflecting the novelty of the product. Duo ULT is widely used throughout Europe, the Middle East, Asia, and Australasia. During the company's current financial year, the product will have been used in over eight million disinfection procedures of ultrasound probes worldwide.

The FDA's De Novo review and approval process stipulates a 150-day decision timeframe. Additional data requests are commonplace, and the FDA website states that the average duration for review and approval is approximately 11 months. Tristel is also proceeding with the state registration of another version of Duo which has been approved by the US EPA for the disinfection of general medical surfaces. The company has received 24 state approvals and anticipates that all others will have been received by the end of 2022. Tristel will manufacture and distribute both Duo products via its commercial partnership with Parker.

"After five years of testing and data generation we are very pleased to have finally submitted our De Novo request for approval to the FDA. We have made an investment of GBP 2.8 million in the project which has all been expensed," said Paul Swinney, Chief Executive of Tristel plc. "The United States is the largest ultrasound market in the world and our competitors will be the same as those we compete with in all our other markets worldwide. To our knowledge no new high-level disinfectant has been approved by the FDA and introduced into the United States since 2011, other than variants of previously approved products. Duo ULT is recognized as a leading high-level disinfectant throughout the rest of the world, and our entry into the United States market will be a significant inflection point for the company."

Related Links:
Parker Laboratories Inc.
Tristel plc

Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
New
Computed Tomography (CT) Scanner
Aquilion Serve SP
Oncology Information System
RayCare
New
Ultrasound Software
UltraExtend NX

Print article

Channels

Radiography

view channel
:	Image: The AI model could be a valuable adjunct to human radiologists in breast cancer diagnoses and risk prediction (Photo courtesy of 123RF)

AI Model Predicts 5-Year Breast Cancer Risk from Mammograms

Approximately 13% of U.S. women, or one in every eight, are predicted to develop invasive breast cancer over their lifetime, with 1 in 39 women (3%) succumbing to the illness, according to the American... Read more

Nuclear Medicine

view channel
Image: The AI system uses scintigraphy imaging for early diagnosis of cardiac amyloidosis (Photo courtesy of 123RF)

AI System Automatically and Reliably Detects Cardiac Amyloidosis Using Scintigraphy Imaging

Cardiac amyloidosis, a condition characterized by the buildup of abnormal protein deposits (amyloids) in the heart muscle, severely affects heart function and can lead to heart failure or death without... Read more

General/Advanced Imaging

view channel
Image: The CIARTIC Move self-driving mobile C-arm has received FDA clearance (Photo courtesy of Siemens)

Self-Driving Mobile C-Arm Reduces Imaging Time during Surgery

Intraoperative imaging faces significant challenges due to staff shortages and the high demands placed on surgical teams in the operating room (OR). A common challenge during many OR procedures is the... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.